Insights

Strategic Partnerships Leverage existing collaborations with Biogen, Janssen, Roche, Pfizer, Vertex and Novartis to expand digital biomarker offerings into broader neuroscience, MS care pathways, and clinical research programs, highlighting Ad Scientiam as a validated remote monitoring partner.

Clinical Validation Position MSCopilot and upcoming digital biomarker solutions as validated, CE-marked tools with real-world utility for continuous MS monitoring, enabling conversations with hospitals and pharmaceutical sponsors about remote patient management and trial endpoints.

US Expansion Capitalize on the MS-FLOWER project launch in the US to open enterprise deals with US healthcare providers and research networks seeking integrated care workflows that embed MSCopilot into routine MS management and clinical decision support.

Funding Quiet Opportunity The recent growth capital backing after a major client setback signals availability of capital for growth initiatives; pursue opportunities in sales-led expansions, product line extensions, and regional partnerships to diversify revenue streams.

Diverse Disease Focus Target neuroscience, rare diseases, and mental health verticals where digital biomarkers can provide continuous monitoring; propose pilot programs with hospitals or pharma sponsors to validate new indications beyond MS, expanding total addressable market.

Similar companies to Ad Scientiam

Ad Scientiam Tech Stack

Ad Scientiam uses 8 technology products and services including Amazon Web Services, Firebase, Microsoft SQL Server, and more. Explore Ad Scientiam's tech stack below.

Media & News

Ad Scientiam's Email Address Formats

Ad Scientiam uses at least 1 email format:
Ad Scientiam Email FormatsExamplePercentage
FLast@adscientiam.comJDoe@adscientiam.com
100%

Frequently Asked Questions

What is Ad Scientiam's official website and social media links?

Minus sign iconPlus sign icon
Ad Scientiam's official website is adscientiam.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Ad Scientiam generate?

Minus sign iconPlus sign icon
As of August 2026, Ad Scientiam's annual revenue is estimated to be <$1M.

What is Ad Scientiam's NAICS code?

Minus sign iconPlus sign icon
Ad Scientiam's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Ad Scientiam have currently?

Minus sign iconPlus sign icon
As of August 2026, Ad Scientiam has approximately 61 employees across 3 continents, including Europe, Africa and North America. Key team members include Chief Scientific Officer: L. C., Chief Medical Officer: S. Z. and President: M. L. Explore Ad Scientiam's employee directory with LeadIQ.

What industry does Ad Scientiam belong to?

Minus sign iconPlus sign icon
Ad Scientiam operates in the Medical Equipment Manufacturing industry.

What technology does Ad Scientiam use?

Minus sign iconPlus sign icon
Ad Scientiam's tech stack includes Amazon Web Services, Firebase, Microsoft SQL Server, MongoDB, SonarQube, Google Cloud Platform, Notion and Microsoft Azure.

What is Ad Scientiam's email format?

Minus sign iconPlus sign icon
Ad Scientiam's email format typically follows the pattern of FLast@adscientiam.com. Find more Ad Scientiam email formats with LeadIQ.

How much funding has Ad Scientiam raised to date?

Minus sign iconPlus sign icon
As of August 2026, Ad Scientiam has raised $8.1M in funding. The last funding round occurred on Nov 05, 2025 for $2.3M.

When was Ad Scientiam founded?

Minus sign iconPlus sign icon
Ad Scientiam was founded in 2013.
Ad Scientiam logo

Ad Scientiam

Medical Equipment ManufacturingÎle-de-France, France51-200 Employees

Ad Scientiam is a medical equipment manufacturer based in Paris, France, focused on measuring and monitoring the progression of serious and disabling diseases in real life. The company designs and clinically validates digital biomarkers to reveal disease evolutions that are not easily detected through traditional means, with the aim of enabling patients to participate actively in their care and helping healthcare professionals tailor treatment more effectively. Its work supports ongoing development of future therapies and seeks to reduce the societal and economic impact of conditions such as multiple sclerosis, neuroscience disorders, rare diseases, and mental health issues. The organization serves hospital institutions and pharmaceutical partners, including collaborations and studies with entities in neuroscience and immunology, and has launched MSCopilot, a CE-marked medical device for self-assessment in multiple sclerosis, with further validation efforts underway for additional indications. Recent activity includes announcements of new projects and international studies, reflecting active engagement in expanding its digital biomarker platform for routine care and remote monitoring.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2013
Employees
51-200

Section iconFunding & Financials

  • $8.1M

    Ad Scientiam has raised a total of $8.1M of funding over 3 rounds. Their latest funding round was raised on Nov 05, 2025 in the amount of $2.3M as a Venture Round.

  • <$1M

    Ad Scientiam's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.